Novo Nordisk B Insulin

Novo Nordisk to cap insulin prices in Minnesota settlement

All Minnesotans can now get insulin for just $35 a month

ST. PAUL, Minn. – All Minnesotans, whether they have insurance or not, will be able to buy insulin products for $35 a month for the next five years.

KARE 11 · 2d

Novo Norodisk caps insulin prices at $35 for Minnesotans

Now Novo Nordisk is required to provide insulin products at $35 per monthly prescription for customers paying with cash. The settlement also requires all three companies to use a texting system to raise awareness of low-cost insulin options, according to the press release.

Reuters on MSN · 3d

Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes drug.

CBS Minnesota on MSN · 3d

Minnesota AG announces Novo Nordisk settlement capping monthly insulin payments at $35

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable prices that led several diabetics to ration their medications with fatal consequences.

Novo Nordisk’s Ozempic Gets FDA Approval

CNBC on MSN · 2d

FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding use in U.S.

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a gradual loss of kidney function.

The Gazette · 2d

US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients

KITV · 1d

FDA approves Ozempic to treat kidney disease in diabetes patients

The FDA approved Ozempic to treat kidney disease in Type 2 diabetes patients after trials showed it reduces the risk of disease progression, Novo Nordisk announced.

New Hampshire Union Leader13d

Novo's Ozempic, Wegovy picked for Medicare price negotiations

Novo Nordisk’s blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

PharmiWeb3d

Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity

Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.

13d

LVMH overtakes Novo Nordisk as Europe’s most valuable company

Luxury bellwether regains crown as drugmaker slips on concerns it will have to cut weight loss medication prices in US ...

New Hampshire Union Leader13d

U.S. targets Novo Nordisk's Ozempic and Wegovy for Medicare price talks

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results